Top 100 Quotes & Sayings by Scott Gottlieb - Page 2

Many inherited disorders can perpetuate poverty by leading to disabilities that disrupt people's ability to work. In turn, someone's capacity to secure an effective new cure for these diseases can mean the difference between a life led productively, or one plagued by infirmity.

We need to make sure that access to a curative drug doesn't become a yardstick by which poverty is eventually measured. Doing so requires a shared commitment between innovators and the insurance plans that are harder pressed to offer these advances to the poor.

Obamacare mandates a largely uniform structure and set of benefits and insurance design across the entire country. It leaves consumers with very little real choice of the health benefits they want.

The fact is that Medicaid doesn't even serve well the medical needs of people who should be its principal focus - Americans who are poor in large part because their chronic health problems leave them unable to earn a stable income.

Obamacare is making the market for health care less competitive.

Creative destruction is an increasingly prominent feature of modern medical practice.

In the U.S, Zika outbreaks are hopefully going to be easy to isolate. The biggest threat is likely to be from the fear Zika sows, especially among expectant moms.

One of the striking features of the early episodes of AMC's hit television show 'Mad Men' is the similarities in the lifestyle enjoyed by the lowest paid members of Don Draper's advertising company and its wealthy partners.

By law and institutional culture, FDA seeks to apply a single tool to its approach to regulation - the requirement for pre-market approval. The agency is accustomed to compelling innovators to submit evidence to FDA and seek permission for marketing.

While faulty information from a digital health tool can influence people to make bad decisions, the risks are far lower than those posed by the usual products FDA subjects to pre-market review.

Even with all its political bells and whistles, the Obamacare plans increasingly resemble Medicaid in terms of networks and drug lists.

Accurate diagnostics are key to enabling successful public health measures.

President Obama famously promised that the Affordable Care Act would not only slow the growth in health care costs, but would also reverse these trends, making the average health insurance plan cheaper. That isn't happening.

As Apple advances the medical promise of its watch and smartphones, it has also made clear that its foremost aim is to steer clear of Food and Drug Administration regulation.

Under Obamacare, doctors have been strained by costly new regulations, intricate payment 'reforms' that tie their Medicare reimbursement to complex federal reporting requirements, and mandates that they install and make 'meaningful' use of electronic health records.

Gene therapies and other treatments that can cure - not just treat - disease are going to be expensive. All of the cost of innovating and reaping an economic return may need to be recouped in a single payment.

The spread of HIV through contaminated blood was a tragic illustration of the risk that blood products could harbor undetectable and latent infection that's only revealed once it's widely distributed.

One of the noxious features of Obamacare was its forced march into a single, federally designed package of health benefits.

One of the untold elements of the rapid decay underway in the Obamacare exchanges is the massive shift toward the Medicaid managed care companies, and away from the traditional commercial insurers like UnitedHealth Group and Aetna.

Obamacare has made insurance costlier and far less comprehensive.

In short order, Obamacare is evolving into a Medicaid marketplace. Not only in terms of the design and quality of the narrow-network plans that are being offered, but in the actual carriers that sell those policies.

Science offers the chance to cure debilitating and once-intractable disorders like hemophilia and sickle cell disease. But we need to make sure the ability to access these therapies, or the risk that someone can be locked out of them, doesn't widen gaps between the rich and poor.

The period of time between the uncovering of some fundamental scientific finding that underpinned a medical advance, and the realization of the corresponding advance in the form of a new drug or medical technique that improves the health of patients, is being continually hastened.

The ACA purposely constrains choice as a top-down means of cost control. Obamacare isn't a consumer-driven, high-deductible scheme. It's hollow coverage.

The nature of food processing had changed substantially in America. Much of it owed to corresponding changes in food packaging and the logistics for faster shipping. The scope of outbreak from foodborne illness no longer has a clear geographic boundary.

For one thing, Medicaid is an inefficient if not ineffective platform for redistributing income. It doesn't get the dollars to poor people in forms that they can best use. Dollars are laundered through healthcare benefits that people may not need. It also means propping up a lot of healthcare interests rather than individual Americans.

Zika is an addressable threat. While it falls outside of the regular routine of public health preparedness, we shouldn't be scrambling for new resources each time a threat like Zika starts to emerge.

Before Obamacare, insurance networks typically covered an entire state. Under Obamacare, insurers are able to bid to offer coverage mostly on a county-by-county basis. It means that health plans only need to fashion doctor networks as wide as the county that they're bidding to offer coverage in.

EpiPen is not unique. It falls into a category of old drugs, many of which should have long been subject to generic competition.

Before Obamacare, many working class Americans had an upper middle class healthcare benefit that they got at work.

The overly engineered, overly regulated market that Obamacare created resulted in restrictive health care plans that provide little choice, and coverage that is far too costly for what the plans offer.

Over the years, EpiPen's manufacturer, Mylan, made meaningful modifications to its auto-injector pen. The company maintains some important intellectual property around these revisions. Mylan rightly argues that these features differentiate its device.

There's a big difference between apps that help you manage your medical information and draw clues from your own bodies, and those that seek to actively doctor you.

Obamacare's costly regulations mean that the mix of people who sign up are tending to be older and sicker. Many young and otherwise healthy individuals continue to be priced out of the exchanges, even after the benefit of federal subsidies are baked into their costs.

Trying to stretch the mission of a health program like Medicaid, as a way to launder redistributionist goals, ends up serving nobody well.

What makes the EpiPen unique is its delivery vehicle - an auto-injector that's packaged in a convenient, pen-like device. The product's key attribute is its ability to reliably deliver accurate doses of the essential medicine.

A major part of the conservative plans to reform Medicaid turn on the assumption that states will be better able to manage the program, and deliver its benefits, free from all the intrusive regulation that Washington imposes.

From West Nile to swine flu to Ebola to the global outbreak of dengue fever, the capacity to deal with threats like Zika must be designed into our preparedness posture.

The ability of working class Americans to bargain for health coverage at work gave them access to the same basic packages of benefits as executive management teams.

The pace at which fundamental discoveries of basic science are being uncovered is accelerating, as is the speed at which medical practice is being transformed by these inventions.